CIK 0002070849 · Non-accelerated filer<br>Emerging growth company
BillionToOne, Inc.
Sign in to watch- Ticker
- BLLN
- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811082020
- Phone
- 650-460-2551
- Business address
- 1035 O'BRIEN DRIVE, MENLO PARK, CA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $26,737,121
- in 19 filings, $26.7M under 10b5-1 plans
Net −$26,737,121. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-07-13 | Tsao David Chief Technology Officer | Sale 10b5-1 | −1,725 | $124.65 | $215K | 5,863 |
| 2026-07-13 | Tsao David Chief Technology Officer | Sale 10b5-1 | −3,835 | $125.76 | $482K | 2,028 |
| 2026-07-13 | Tsao David Chief Technology Officer | Sale 10b5-1 | −1,028 | $126.90 | $130K | 1,000 |
| 2026-07-13 | Tsao David Chief Technology Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −10,000 | $2.80 | $28K | 610,000 |
| 2026-07-13 | Tsao David Chief Technology Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −10,000 | $2.80 | $28K | 600,000 |
| 2026-07-13 | ten Bosch John Roderick SVP of Laboratory Operations | Sale 10b5-1 | −1,417 | $125.46 | $178K | 32,135 |
| 2026-07-13 | ten Bosch John Roderick SVP of Laboratory Operations | Sale 10b5-1 | −1,417 | $125.46 | $178K | 30,718 |
| 2026-07-13 | ten Bosch John Roderick SVP of Laboratory Operations | Sale 10b5-1 | −1,417 | $125.46 | $178K | 29,301 |
| 2026-07-09 | Atay Oguzhan Chairman and CEO | Option exercise 10b5-1 | +12,500 | $2.80 | $35K | 12,500 |
| 2026-07-09 | Atay Oguzhan Chairman and CEO | Sale 10b5-1 | −7,489 | $125.43 | $939K | 5,011 |
| 2026-07-09 | Atay Oguzhan Chairman and CEO | Sale 10b5-1 | −2,002 | $126.48 | $253K | 3,009 |
| 2026-07-09 | Atay Oguzhan Chairman and CEO | Sale 10b5-1 | −2,657 | $127.44 | $339K | 352 |
| 2026-07-09 | Atay Oguzhan Chairman and CEO | Sale 10b5-1 | −352 | $128.23 | $45K | 0 |
| 2026-07-09 | Atay Oguzhan Chairman and CEO | Option exercise · Stock Option (right to buy) 10b5-1 | −12,500 | $2.80 | $35K | 575,000 |
| 2026-07-09 | Sakakibara Shan Riku Chief Product Officer | Option exercise 10b5-1 | +174 | $8.65 | $2K | 208,174 |
| 2026-07-09 | Sakakibara Shan Riku Chief Product Officer | Option exercise 10b5-1 | +1,117 | $30.78 | $34K | 209,291 |
| 2026-07-09 | Sakakibara Shan Riku Chief Product Officer | Option exercise 10b5-1 | +1,355 | $30.78 | $42K | 210,646 |
| 2026-07-09 | Sakakibara Shan Riku Chief Product Officer | Option exercise 10b5-1 | +1,354 | $30.78 | $42K | 212,000 |
| 2026-07-09 | Sakakibara Shan Riku Chief Product Officer | Sale 10b5-1 | −4,000 | $125.00 | $500K | 208,000 |
| 2026-07-09 | Sakakibara Shan Riku Chief Product Officer | Sale 10b5-1 | −174 | $125.00 | $22K | 207,826 |
Page 13 of 32 · 639 trades